Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms

British Journal of Haematology

Volumn 147, Issue 4, 2009, Pages 495-506

  Grimwade, Lizz F ^a   Happerfield, Lisa ^a   Tristram, Colin ^b   McIntosh, Gary ^b   Rees, Mark ^b   Bench, Anthony J ^a   Boyd, Elaine M ^a   Hall, Marie ^b   Quinn, Amy ^b   Piggott, Nigel ^b   Scorer, Paul ^b   Scott, Mike A ^a   Erber, Wendy N ^a,c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b Leica Biosystems Newcastle Ltd   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Akt; Myeloproliferative neoplasms; Phosphorylation; STAT5

Indexed keywords

JANUS KINASE 2; MONOCLONAL ANTIBODY; PHOSPHOPROTEIN; PROTEIN KINASE B; STAT5 PROTEIN; STEM CELL FACTOR; THROMBOPOIETIN RECEPTOR;

ADULT; ARTICLE; BONE MARROW; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EXON; FEMALE; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MAST CELL; MEGAKARYOCYTE; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC MASTOCYTOSIS; THROMBOCYTHEMIA; UPREGULATION;

EID: 70350446987     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07870.x     Document Type: Article

References (49)

1. Aboudola, S., Murugensan, G., Szpurka, H., Ramsingh, G., Zhao, X., Prescott, N., Tubbs, R., Maciejewski, J. Hsi, E. (2007) Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. American Journal of Surgical Pathology, 31, 233 239.
2. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N., Green, A.R. Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
3. Beer, P.A., Campbell, P.J., Scott, L.M., Bench, A.J., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Hasselbalch, H.C., Bowman, R., Wheatley, K., Buck, G., Harrison, C.N. Green, A.R. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 112, 141 149.
4. Bogani, C., Guglielmelli, P., Antonioli, E., Pancrazzi, A., Bosi, A. Vannucchi, A. (2007) B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica, 92, 258 259.
5. Boyd, E., Bench, A., Goday-Fernandez, A., Vaghela, K., Scott, M., Bareford, D., Green, A. Erber, W. (2009) A simple diagnostic test for MPL exon 10 mutations in myeloproliferative neoplasms. British Journal of Haematology, 145, 64.
6. Bunting, K., Xie, X., Warshawsky, I. Hsi, E. (2007) Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD. Blood, 110, 2775 2776.
7. Chian, R.J., Young, S., Danilkovitch-Miagkova, A., Ronnstrand, L., Leonard, E., Ferrao, P., Ashman, L. Linnekin, D. (2001) Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood, 98, 1365 1372.
8. Garcia-Montero, A., Jara-Acevedo, M., Teodosio, C., Sanchez, M., Nunez, R., Prados, A., Aldanondo, I., Sanchez, L., Dominguez, M., Botana, L., Sanchez-Jimenez, F., Sotlar, K., Almeida, J., Escribano, L. Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, 2366 2372.
9. Garcon, L., Rivat, C., James, C., Lacout, C., Camara-Clayette, V., Ugo, V., Lecluse, Y., Bennaceur-Griscelli, A. Vainchenker, W. (2006) Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood, 108, 1551 1554.
10. Gery, S., Gueller, S., Chumakova, K., Kawamata, N., Liu, L. Koeffler, H. (2007) Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood, 110, 3360 3364.
11. Gibson, S.E., Schade, A.E., Szpurka, H., Bak, B., Maciejewski, J.P. Hsi, E.D. (2008) Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. Human Pathology, 39, 1111 1114.
12. Grimwade, L., Happerfield, L., Bench, A.J. Erber, W.N. (2008) Akt and STAT5 signalling proteins are phosphorylated in systemic mastocytosis: immunocytochemical demonstration by double labelling. International Journal of Laboratory Hematology, 30 (Suppl.1 58 147.
13. Harir, N., Pecquet, C., Kerenyi, M., Sonneck, K., Kovacic, B., Nyga, R., Brevet, M., Dhennin, I., Gouilleux-Gruart, V., Beug, H., Valent, P., Lassoued, K., Moriggl, R. Gouilleux, F. (2007) Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 109, 1678 1686.
14. Harir, N., Boudot, C., Friedbichler, K., Sonneck, K., Kondo, R., Martin-Lannerée, S., Kenner, L., Kerenyi, M., Yahiaoui, S., Gouilleux-Gruart, V., Gondry, J., Bénit, L., Dusanter-Fourt, I., Lassoued, K., Valent, P., Moriggl, R. Gouilleux, F. (2008) Oncogenic kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood, 112, 2463 2473.
15. Ishii, T., Bruno, E., Hoffman, R. Xu, M. (2006) Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood, 108, 3128 3134.
16. James, C., Ugo, V., Le Couedlc, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144 1148. (Pubitemid 40663494)
17. Jones, A., Cross, N., White, H., Green, A. Scott, L. (2008) Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica, 93, 1560 1564.
18. Kilpivaara, O. Levine, R. (2008) JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia, 20, 1813 1817.
19. Kota, J., Caceres, N. Constantinescu, S.N. (2008) Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia, 20, 1828 1840.
20. Lasho, T., Mesa, R., Gilliland, D. Tefferi, A. (2005) Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. British Journal of Haematology, 130, 797 799.
21. Levine, R.L. Gilliland, D.G. (2008) Myeloproliferative disorders. Blood, 112, 2190 2198.
22. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., S, F., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
23. Levine, R.L., Pardanani, A., Tefferi, A. Gilliland, D.G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews: Cancer, 7, 673 683.
24. Lim, K.H., Pardanani, A. Tefferi, A. (2008) KIT and mastocytosis. Acta Haematologica, 119, 194 198.
25. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D.G. Lodish, H. (2005) Expression of a homodimeric type 1 cytokine receptor is required for JAK2 V617F-mediated transformation. Proceedings of the National Academy of Science of the United States of America, 102, 18962 18967.
26. Ma, W., Kantarjian, H., Zhang, X., Yeh, C., Zhang, Z., Verstovsek, S. Albitar, M. (2009) Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. The Journal of Molecular Diagnostics, 11, 49 53.
27. Mayerhofer, M., Gleixner, K.V., Hoelbl, A., Florian, S., Hoermann, G., Aichberger, K.J., Bilban, M., Esterbauer, H., Krauth, M.T., Sperr, W.R., Longley, J.B., Kralovics, R., Moriggl, R., Zappulla, J., Liblau, R.S., Schwarzinger, I., Sexl, V., Sillaber, C. Valent, P. (2008) Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. Journal of Immunology, 180, 5466 5476.
28. McMullin, M., Bareford, D., Campbell, P., Green, A.R., Harrison, C., Hunt, B., Oscier, D., Polkey, M.I., Reilly, J.T., Rosenthal, E., Ryan, K., Pearson, T.C. Wilkins, B., On behalf of the General Haematology Task Force of the British Committee for Standards in Haematology (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology, 130, 174 195. (Pubitemid 41602518)
29. McMullin, M., Reilly, J.T., Campbell, P., Bareford, D., Green, A.R., Harrison, C. Conneally, E., On behalf of the National Cancer Research Institute, Myeloproliferative Disorder Subgroup and Ryan, K., On behalf of the British Committee for Standards in Haematology (2007) Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology, 138, 821 823.
30. Nakatani, K., Thompson, D.A., Barthel, A., Sakaue, H., Liu, W., Weigel, R.J. Roth, R.A. (1999) Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. Journal of Biological Chemistry, 274, 21528 21532.
31. Nicholson, K.M. Anderson, N.G. (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling, 14, 381 395.
32. Pardanani, A., Lasho, T., Fincke, C., Hanson, C. Tefferi, A. (2007) Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21, 1960 1963.
33. Percy, M.J., Scott, L.M., Erber, W.N., Harrison, C.N., Reilly, J.T., Jones, F.G., Green, A.R. McMullin, M.F. (2007) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica, 92, 1607 1614.
34. Schindler, C., Shuai, K., Prezioso, V. Darnell, J. (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 257, 809 813.
35. Schindler, C., Levy, D. Decker, T. (2007) JAK-STAT signalling: from interferons to cytokines. Journal of Biological Chemistry, 282, 20059 20063.
36. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459 468.
37. Shaui, K., Horvath, C., Tsai Huang, L., Qureshi, S., Cowburn, D. Darnell, J. (1994) Interferon activation of the transcription factor STAT91 involves dimerisation through SH2-phosphotyroysl pepride interactions. Cell, 76, 821 828.
38. Shide, K., Shimoda, H.K., Kumano, T., Karube, K., Kameda, T., Takenaka, K., Oku, S., Abe, H., Katayose, K.S., Kubuki, Y., Kusumoto, K., Hasuike, S., Tahara, Y., Nagata, K., Matsuda, T., Ohshima, K., Harada, M. Shimoda, K. (2008) Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia, 22, 87 95.
39. Shivakrupa, R., Bernstein, A., Watring, N. Linnekin, D. (2003) Phosphatidylinositol 3 kinase is required for growth of mast cells expressing kit catalytic domain mutant. Cancer Research, 63, 4412 4419.
40. Sidon, P., Heimann, P., Lambert, F., Dessars, B., Robin, V. El Housni, H. (2006) Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. Clinical Chemistry, 52, 1436 1438.
41. Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I. Fernandez-Luna, J. (1998) Expression of Bcl-x in erythroid precursors from patients with polycythaemia vera. New England Journal of Medicine, 338, 564 571.
42. Sundstrom, M., Vliagoftis, H., Karlberg, P., Butterfield, J.H., Nilsson, K., Metcalfe, D.D. Nilsson, G. (2003) Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology, 108, 89 97.
43. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S., Stein, H., Thiele, J. Vardiman, J.W. (eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Press, Geneva, Switzerland.
44. Taylor, M., Sehgal, D., Raffeld, M., Obiakor, H., Akin, C., Mage, R. Metcalfe, D. (2004) Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. The Journal of Molecular Diagnostics, 6, 335 342.
45. Teofili, L., Martini, M., Cenci, T., Petrucci, G., Torti, L., Storti, S., Guidi, F., Leone, G. Larocca, L.M. (2007) Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood, 110, 354 359.
46. Toro, T., Hsieh, F.H., Bodo, J., Dong, H.Y. Hsi, E.D. (2007) Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation. British Journal of Haematology, 139, 31 40.
47. Zappulla, J.P., Dubreuil, P., Desbois, S., Létard, S., Hamouda, N.B., Daëron, M., Delsol, G., Arock, M. Liblau, R.S. (2005) Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. Journal of Experimental Medicine, 202, 1635 1641.
48. Zeuner, A., Pedini, F., Signore, M., Ruscio, G., Messina, C., Tafuri, A., Girelli, G., Peschle, C. De Maria, R. (2006) Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood, 107, 3495 3502.
49. Zhao, R., Follows, G., Beer, P., Scott, L., Huntly, B., Green, A. Alexander, D. (2008) Inhibition of the Bcl-xl deamination pathway in myeloproliferative disorders. New England Journal of Medicine, 359, 2778 2789.